All In Biotech

Drug Trial Radar · NCT00006145

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay

Last checked: Nov 20, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Aug 2000

Primary completion

Not stated

Study completion Feb 2006

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in people with HIV.

Conditions

  • Cytomegalovirus Infections
  • HIV Infections

Interventions

  • ValganciclovirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

57 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Therapeutics CRS

    Birmingham, Alabama

  • USC CRS

    Los Angeles, California

  • UCLA CARE Center CRS

    Los Angeles, California

  • Stanford CRS

    Palo Alto, California

  • Ucsd, Avrc Crs

    San Diego, California

  • Ucsf Aids Crs

    San Francisco, California

  • Santa Clara Valley Med. Ctr.

    San Jose, California

  • San Mateo County AIDS Program

    San Mateo, California

  • Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic

    San Rafael, California

  • University of Colorado Hospital CRS

    Aurora, Colorado

  • Georgetown University CRS (GU CRS)

    Washington D.C., District of Columbia

  • Univ. of Miami AIDS CRS

    Miami, Florida

  • The Ponce de Leon Ctr. CRS

    Atlanta, Georgia

  • Univ. of Hawaii at Manoa, Leahi Hosp.

    Honolulu, Hawaii

  • Northwestern University CRS

    Chicago, Illinois

  • Cook County Hosp. CORE Ctr.

    Chicago, Illinois

  • Rush Univ. Med. Ctr. ACTG CRS

    Chicago, Illinois

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic

    Indianapolis, Indiana

  • Indiana Univ. School of Medicine, Wishard Memorial

    Indianapolis, Indiana

  • Methodist Hosp. of Indiana

    Indianapolis, Indiana

  • Univ. of Iowa Healthcare, Div. of Infectious Diseases

    Iowa City, Iowa

  • IHV Baltimore Treatment CRS

    Baltimore, Maryland

  • Johns Hopkins Adult AIDS CRS

    Baltimore, Maryland

  • Massachusetts General Hospital ACTG CRS

    Boston, Massachusetts

  • Bmc Actg Crs

    Boston, Massachusetts

  • BMC, Div. of Ped Infectious Diseases

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS

    Boston, Massachusetts

  • Brigham and Women's Hosp. ACTG CRS

    Boston, Massachusetts

  • SSTAR, Family Healthcare Ctr.

    Fall River, Massachusetts

  • University of Minnesota, ACTU

    Minneapolis, Minnesota

  • Washington U CRS

    St Louis, Missouri

  • Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.

    Omaha, Nebraska

  • SUNY - Buffalo, Erie County Medical Ctr.

    Buffalo, New York

  • Beth Israel Med. Ctr., ACTU

    New York, New York

  • Cornell CRS

    New York, New York

  • NY Univ. HIV/AIDS CRS

    New York, New York

  • Weill Med. College of Cornell Univ., The Cornell CTU

    New York, New York

  • Columbia Univ., HIV Prevention and Treatment Medical Ctr.

    New York, New York

  • AIDS Care CRS

    Rochester, New York

  • McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit

    Rochester, New York

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.